698 related articles for article (PubMed ID: 29289555)
1. Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment.
Patel HK; Bihani T
Pharmacol Ther; 2018 Jun; 186():1-24. PubMed ID: 29289555
[TBL] [Abstract][Full Text] [Related]
2. Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer.
Lu Y; Liu W
J Med Chem; 2020 Dec; 63(24):15094-15114. PubMed ID: 33138369
[TBL] [Abstract][Full Text] [Related]
3. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Baumann CK; Castiglione-Gertsch M
Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
[TBL] [Abstract][Full Text] [Related]
4. Selective Estrogen receptor degraders (SERDs) for the treatment of breast cancer: An overview.
Bhatia N; Hazra S; Thareja S
Eur J Med Chem; 2023 Aug; 256():115422. PubMed ID: 37163948
[TBL] [Abstract][Full Text] [Related]
5. Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective.
Hernando C; Ortega-Morillo B; Tapia M; Moragón S; Martínez MT; Eroles P; Garrido-Cano I; Adam-Artigues A; Lluch A; Bermejo B; Cejalvo JM
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360578
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive Transcriptomic and Proteomic Analyses Identify a Candidate Gene Set in Cross-Resistance for Endocrine Therapy in Breast Cancer.
Li CL; Moi SH; Lin HS; Hou MF; Chen FM; Shih SL; Kan JY; Kao CN; Wu YC; Kao LC; Chen YH; Lee YC; Chiang CP
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142451
[TBL] [Abstract][Full Text] [Related]
7. Selective oestrogen receptor degraders in breast cancer: a review and perspectives.
Gombos A
Curr Opin Oncol; 2019 Sep; 31(5):424-429. PubMed ID: 31335829
[TBL] [Abstract][Full Text] [Related]
8. The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options.
Wang Y; Tang SC
Cancer Metastasis Rev; 2022 Dec; 41(4):975-990. PubMed ID: 36229710
[TBL] [Abstract][Full Text] [Related]
9. The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer.
McDonnell DP; Wardell SE
Curr Opin Pharmacol; 2010 Dec; 10(6):620-8. PubMed ID: 20926342
[TBL] [Abstract][Full Text] [Related]
10. Accelerating drug development in breast cancer: New frontiers for ER inhibition.
Ferraro E; Walsh EM; Tao JJ; Chandarlapaty S; Jhaveri K
Cancer Treat Rev; 2022 Sep; 109():102432. PubMed ID: 35839531
[TBL] [Abstract][Full Text] [Related]
11. Molecularly targeted endocrine therapies for breast cancer.
Orlando L; Schiavone P; Fedele P; Calvani N; Nacci A; Rizzo P; Marino A; D'Amico M; Sponziello F; Mazzoni E; Cinefra M; Fazio N; Maiello E; Silvestris N; Colucci G; Cinieri S
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S67-71. PubMed ID: 21129614
[TBL] [Abstract][Full Text] [Related]
12. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance.
Lewis JS; Jordan VC
Mutat Res; 2005 Dec; 591(1-2):247-63. PubMed ID: 16083919
[TBL] [Abstract][Full Text] [Related]
13. Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer.
Xiong R; Zhao J; Gutgesell LM; Wang Y; Lee S; Karumudi B; Zhao H; Lu Y; Tonetti DA; Thatcher GR
J Med Chem; 2017 Feb; 60(4):1325-1342. PubMed ID: 28117994
[TBL] [Abstract][Full Text] [Related]
14. Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: elacestrant as the poster-child.
Keenan JC; Medford AJ; Dai CS; Wander SA; Spring LM; Bardia A
Expert Rev Anticancer Ther; 2024 Jun; 24(6):397-405. PubMed ID: 38642015
[TBL] [Abstract][Full Text] [Related]
15. Current and emerging estrogen receptor-targeted therapies for the treatment of breast cancer.
Haines CN; Wardell SE; McDonnell DP
Essays Biochem; 2021 Dec; 65(6):985-1001. PubMed ID: 34328178
[TBL] [Abstract][Full Text] [Related]
16. Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER
Bihani T; Patel HK; Arlt H; Tao N; Jiang H; Brown JL; Purandare DM; Hattersley G; Garner F
Clin Cancer Res; 2017 Aug; 23(16):4793-4804. PubMed ID: 28473534
[No Abstract] [Full Text] [Related]
17. Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (2015-present).
Scott JS; Barlaam B
Expert Opin Ther Pat; 2022 Feb; 32(2):131-151. PubMed ID: 34763600
[TBL] [Abstract][Full Text] [Related]
18. Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance.
Sengupta S; Jordan VC
Adv Exp Med Biol; 2008; 630():206-19. PubMed ID: 18637493
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of Selective Estrogen Receptor Modulators in Breast Cancer Therapy: An Update.
Das A; Lavanya KJ; Nandini ; Kaur K; Jaitak V
Curr Med Chem; 2023; 30(29):3287-3314. PubMed ID: 36201273
[TBL] [Abstract][Full Text] [Related]
20. Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs).
Li Y; Zhang S; Zhang J; Hu Z; Xiao Y; Huang J; Dong C; Huang S; Zhou HB
Eur J Med Chem; 2019 Jun; 172():48-61. PubMed ID: 30939353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]